31 results about "Ocular surface disease" patented technology

The invention relates to the technical field of deep learning and medical image recognition, and discloses a small target segmentation method for ocular surface diseases. According to the scheme provided by the invention, ResNeXt packet convolution is introduced into Backbone to enhance feature diversity, a channel attention (CA) module is added behind an output layer to optimize a dependency relationship between channels, and a bottom-up feature enhancement branch is added in a feature pyramid (FPN) structure to form a bidirectional information flow, so that semantic expression and spatial positioning are considered. In combination with an improved region generation network (RPN), an ROI Align and a multi-task loss function (classification loss Lcls, mask loss Lmask and bounding box loss Lbox), the small target segmentation performance can be remarkably improved while the calculation efficiency is kept. In a slit lamp eye surface data set experiment, the small focus Dice coefficient of the method is improved by about 12%, the omission factor is reduced by 9%, the defects of an existing method in small target segmentation are effectively overcome, and the method has good clinical application value.

The invention discloses an ocular surface illumination treatment device and method, and belongs to the technical field of ophthalmology medical equipment and treatment. The device comprises an infrared camera module, a computer terminal analysis control module, an optical power detection module, a mechanical adjustment module, a safety switch module and an illumination module. Wherein the infrared camera module comprises an infrared CCD (Charge Coupled Device) camera and a near-infrared light source which are arranged at a preset included angle and can collect eye images and transmit the eye images to the computer terminal, and the highest recording speed of the infrared camera module is not lower than 200 frames per second; and the computer terminal analyzes the image to obtain pupil positions, diameters and distances, and adjusts relative positions of a shielding device and a lens group in the light path of the illumination module, the axis of the light path and the distance between left and right lens cones, so that the central dark area of the annular light spot is matched and overlapped with the pupil. Eye images are collected and processed firstly, then light spots and the lens cone are adjusted, finally phototherapy and real-time monitoring are carried out, light can be prevented from entering the fundus, the treatment safety is improved, and the device is suitable for ocular surface diseases such as xerophthalmia.

The invention discloses application of ganoderma lucidum exosomes in preparation of corneal injury repair preparations, and belongs to the technical field of biological medicines. The ganoderma lucidum exosome realizes corneal injury repair by promoting corneal endothelial cell proliferation and migration ability, promotes corneal endothelial proliferation and cell migration and accelerates corneal endothelial injury repair through an EGFR / ERK signal channel, can be used for treatment of corneal epithelium defect related ocular surface diseases, corneal lesion and other diseases, and has a wide application prospect. And a new thought is provided for treatment of corneal endothelial diseases.

Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.

Described herein are compositions and methods for treating or preventing skin or ocular surface disorders, such as those associated with bacterial and / or parasitic infections. Bacterial and / or parasitic infections include mites (e.g., Demodex), helminths, protozoa (e.g., amebas (e.g., Acanthamoeba or Cryptosporidiosis)), onchocerciasis, lice, scabies, nematodes, or chlamydia. The compositions and methods include compounds that exhibit immunological activity, keratolytic activity, antihistamine activity, anti-inflammatory activity, and / or other desirable activities. Topical administration of the compositions to the eyelid margin or surrounding area provides therapeutic benefit to patients with ocular surface disorders.

The invention relates to a novel method for precise and early diagnosis to facilitate in time intervention for ocular surface disease (OSD). Therefore, the method is potentially useful for ocular surface disease (OSD) diagnosis in the clinical settings.

The present application provides a medicine for treating ocular surface and corneal epithelial diseases, which has fibroblast growth factor 5 as an effective component. The medicine has the effects of promoting corneal epithelial repair and treating ocular surface diseases caused by fibroblast growth factor 5 (FGF5) gene mutation, and has no toxic side effects.

The invention discloses a terahertz-based stable tear film treatment ocular surface detection system, which comprises a terahertz emission module, an ocular surface detection module, an intelligent control module, an environment perception module and a man-machine interaction module, and is characterized in that the terahertz emission module is used for emitting frequency-adjustable terahertz waves to the ocular surface so as to adjust the molecular structure and energy of ocular surface water; the ocular surface detection module is used for collecting multiple physiological parameters of the ocular surface in real time. The stable tear film treatment ocular surface detection system based on terahertz realizes ocular surface multi-parameter real-time detection, terahertz wave accurate regulation and control and closed-loop linkage of detection and treatment, has environment self-adaption and personalized optimization capabilities, fundamentally adjusts ocular surface water molecule structure and energy, and improves the treatment efficiency. A tear film is stabilized, and accurate detection and long-acting treatment of ocular surface diseases such as xerophthalmia are realized.

The present disclosure provides an ophthalmic formulation comprising: one or more pharmaceutically acceptable excipients; a pharmaceutically active compound capable of reducing the amount or deleterious effects of autoantibodies on the ocular surface, such as IgG; in particular, the present disclosure provides an ophthalmic formulation wherein the pharmaceutically active compound is capable of treating a clinical condition selected from the group consisting of inflammatory, infectious and immunological ocular surface or intraocular diseases that can cause symptoms of ocular discomfort, keratitis, dry eye disease, formation of symblepharon, shortening of the anterior chamber depth, lid margin / conjunctival keratinization, subconjunctival fibrosis, retinal gliosis and glaucoma.

To develop a novel method for treatment of diseases leading to serious corneal and conjunctival epithelial damage resulting from functional impairment of corneal and conjunctival epithelial stem cells, including severe ocular surface disease attributable to chronic graft-versus-host disease.SOLUTION: The present invention provides a prophylactic or treatment agent for severe ocular surface disease for topical administration, comprising apocynin as an active ingredient.SELECTED DRAWING: None

The purpose of the present invention is to develop a novel treatment method for diseases such as severe ocular surface diseases caused by chronic graft-versus-host disease, which cause severe corneal and conjunctival epithelial damage due to dysfunction of corneal and conjunctival epithelial stem cells. SOLUTION: The present invention provides a topically administered agent for preventing or treating severe ocular surface diseases, which contains apocynin as an active ingredient.

Described herein are compositions and methods for the treatment or prevention of dermal or ocular surface disorders, such as those associated with bacterial and / or parasitic infections. Bacterial and / or parasitic infections include mites (e.g., demodex), worms, protozoa (e.g., amoeba (e.g., acanthamoeba or cryptosporidiosis)), onchocerciasis, lice, scabies, nematodes, or chlamydia. Said compositions and methods comprise compounds which demonstrate immunological, keratolytic, anti-histamine, anti-inflammatory, and / or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

The present invention relates to a compound of formula (I) or a stereoisomer, or tautomer, wherein moiety A, R1, and R2 have the same meaning as that defined in the claims and the description. The present invention also relates to the use of such compounds for the prevention and / or treatment of a disease associated with ferroptosis and / or oxytosis such as liver disease, chronic kidney disease, lung disease, ocular surface diseases, wound healing, multiple organ dysfunction syndrome, neurological disease, acute renal failure, ischemia- reperfusion injury, sepsis, prevention of transplant rejection, iron toxicity, iron metabolism- related disease and genetic disorder of GPX4. The present invention also provides pharmaceutical compositions comprising such compounds, as well as the use of the compounds as a medicament and methods of prevention and / or treatment of such diseases.

The purpose of the present invention is to develop a novel method for treating diseases leading to severe corneal and conjunctival epithelial disorder from dysfunction of corneal / conjunctival epithelial stem cells, such as severe ocular surface diseases caused by chronic graft-versus-host disease.　The present invention provides a prophylactic or therapeutic agent for severe ocular surface disease for topical administration, the agent containing apocynin as an active ingredient.

The application discloses a surface-engineered Gouqi-source exosome ophthalmic preparation for treating ocular surface diseases, and belongs to the technical field of ocular surface drug delivery and plant-source exosome preparation. The preparation takes Gouqi-source exosomes as the main body, takes a mucin-related peptide-anchor molecule complex capable of combining with, adsorbing, intertwining or anchoring the ocular mucosa, epithelial sugar absorption or mucin network, and having an ocular surface repair effect as a surface modification unit, and is used for improving the residence capacity of the exosomes on the ocular surface and enhancing the ocular surface repair effect.

Disclosed herein are methods for treating and preventing adverse events, including ocular surface disorders, induced by antibody-drug conjugates (ADCs) using compounds of Formula (I) or a pharmaceutically acceptable salts, solvates, hydrates, stereoisomers, tautomers, racemates or isotopes thereof, wherein the groups R1, R2 and R3 are defined herein. Also disclosed herein are methods for treating cancer using a combination of an ADC and a compound of Formula (I).

The inventions relate to compounds and compositions comprising connexin modulators and their use in dose regimens for the treatment of non-healing or persistent ocular surface or corneal defects and disorders.

This disclosure features clusterin (CLU) as a multifunctional biotherapeutic for promoting ocular nerve regeneration for various ocular conditions. This disclosure features methods of using CLU for treating a subject with an ocular disorder, condition, or disease (e.g., an ocular surface disease, corneal disease or retinal disease). The methods described herein can be used for the treatment of ocular inflammatory conditions involving barrier disruption and nerve loss due to its ability to protect and promote the regeneration of ocular nerves.

The present disclosure provides methods for (a) preparing a patient for an ocular surgery, (b) treating ocular surface diseases in a patient prepared for an ocular surgery, and (c) performing biometric measurements for preparing an ocular surgery, wherein the method comprises topically administering to the eye of the patient a composition comprising about 0.05%-0.1% (w / v) cyclosporin dissolved in a semi-fluorinated alkane, optionally with an alcoholic co-solvent, once to four times per day.

The present invention relates to a compound of formula (I) or a stereoisomer, or tautomer, (I) wherein cycle A, R1, R2, and R3 have the same meaning as that defined in the claims and the description. The present invention also relates to the use of such compounds for the prevention and / or treatment of a disease associated with ferroptosis and / or oxytosis such as liver disease, chronic kidney disease, lung disease, ocular surface diseases, wound healing, multiple organ dysfunction syndrome, neurological disease, acute renal failure, ischemia-reperfusion injury, sepsis, prevention of transplant rejection, iron toxicity, iron metabolism-related disease and genetic disorders of GPX4. The present invention also provides pharmaceutical compositions comprising such compounds, as well as the use of the compounds as a medicament and methods of prevention and / or treatment of such diseases.

Described herein are compositions and methods for the treatment or prevention of dermal or ocular surface disorders, such as those associated with bacterial and / or parasitic infections. Bacterial and / or parasitic infections include mites (e.g., demodex), worms, protozoa (e.g., amoeba (e.g., acanthamoeba or cryptosporidiosis)), onchocerciasis, lice, scabies, nematodes, or chlamydia. Said compositions and methods comprise compounds which demonstrate immunological, keratolytic, anti-histamine, anti-inflammatory, and / or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

The application discloses a nano-coating eye drop, a bioactive nano-coating loaded with a permeable drug and a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The nano-coating eye drop comprises a polyphenol substance, metal ions, liposomes and a permeable drug, the polyphenol substance contains phenolic hydroxyl groups and carbonyl groups, the liposomes contain carbonyl groups, the metal ions form a coordination network with the phenolic hydroxyl groups and the carbonyl groups in the polyphenol substance, the liposomes are embedded in the coordination network through the carbonyl groups to form a porous network structure, and the permeable drug is loaded in the porous network structure. The nano-coating eye drop can rapidly form a stable and adherent nano-coating on an ocular surface after being dropped into the eyes, so that the nano-coating can improve ocular surface diseases through the anti-inflammatory, moisturizing and repair-promoting activities of the nano-coating itself, and continuously release the permeable drug which can penetrate the ocular barrier, so that the double-site synchronous intervention of the ocular surface and the fundus diseases is realized.

This invention relates to spirocyclic barbiturates of general formula (I) or pharmaceutically acceptable salts thereof as MMP9 inhibitors for the treatment of ocular surface diseases, such as, for example, dry eye disease.

The current invention relates to isolated Extracellular Vesicles (EVs) or a pharmaceutical composition comprising an effective amount of said EVs for use in the treatment of an ocular surface disease, wherein said EVs are administered to the eye of a patient suffering from said ocular surface disease, wherein said EVs are MSC (Mesenchymal Stem Cells) derived EVs, preferably umbilical cord MSC-derived EVs, 10 wherein said EVs are associated with albumin and Annexin V, and wherein said EVs are positive for CD44 and CD29.

The present invention relates to a compound of formula (I) or a stereoisomer, or tautomer, wherein R1, R2, R3, and R4 have the same meaning as that defined in the claims and the description. The present invention also relates to the use of such compounds for the prevention and / or treatment of a disease associated with ferroptosis and / or oxytosis such as liver disease, chronic kidney disease, ocular surface diseases, wound healing, multiple organ dysfunction syndrome, neurological disease, acute renal failure, ischemia-reperfusion injury, sepsis, prevention of transplant rejection, and iron metabolism-related disease. The present invention also provides pharmaceutical compositions comprising such compounds, as well as the use of the compounds as a medicament.

Described herein are compositions and methods for the treatment or prevention of dermal or ocular surface disorders. Ocular surface disorders include ocular allergy, dry eye disease, ocular manifestation of graft versus host disease and other inflammatory and / or infectious diseases of the (e.g., anterior) surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate immunological, keratolytic, anti-inflammatory, and / or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

The application discloses a mucous membrane-adhesive polymeric microcarrier loaded with disodium cladribine tetrasodium and a preparation method and application thereof. Sodium alginate is modified by phenylboronic acid to obtain a PBA-Alg polymer; disodium cladribine tetrasodium is mixed with the polymer to obtain a precursor solution; microdroplets are formed by a microfluidic electrospray technology and sprayed into a calcium ion crosslinking solution to be solidified to obtain the microcarrier. In the microcarrier, the phenylboronic acid groups form reversible borate ester bonds with cis-diol groups in the disodium cladribine tetrasodium molecules, so that stable anchoring and continuous release of the drug are realized. The phenylboronic acid groups on the surface of the microcarrier can form dynamic covalent bonds with sialic acid residues in ocular surface mucin, so that long-acting adhesion on the ocular surface is realized; meanwhile, the borate ester bonds are oxidatively cleaved in the presence of excess active oxygen on the ocular surface, so that the active oxygen is consumed and inflammation is inhibited. The microcarrier has a highly uniform size and shear thinning characteristics, and can be safely, comfortably, efficiently and low-frequency used for the treatment of ocular surface diseases such as dry eye.

The present invention relates to a compound of formula (I) or a stereoisomer, or tautomer, wherein R1, R2, and R3 have the same meaning as that defined in the claims and the description, wherein said compound is used as a medicament for oral administration. The present invention also relates to the use of such compounds for the prevention and / or treatment of a disease associated with ferroptosis and / or oxytosis such as liver disease, chronic kidney disease, lung disease, ocular surface diseases, wound healing, multiple organ dysfunction syndrome, neurological disease, acute renal failure, ischemia-reperfusion injury, sepsis, prevention of transplant rejection, iron toxicity, iron metabolism-related disease and genetic disorders of GPX4. The present invention also provides pharmaceutical compositions comprising such compounds, as well as the use of the compounds as medicament for oral administration in methods of prevention and / or treatment of such diseases.

A new method is provided that precisely harmonizes the structural and functional biological processes that lead to the optimal reconstruction of ocular surface disorders. The method consists of the administration of a trilaminar (3D) material, which comprises the mucosa, the basement membrane, and the submucosa of the porcine esophagus in a stabilized conformation of integrated layers, which accurately imitates ocular structures, whose mechanical properties, biocompatibility, and integration into the host's tissues, facilitate the structural and functional restoration of lost or damaged ocular tissues. Through the mimesis of the spatial microenvironments generated by their structure and their functional conjugation with the signals of the host's extracellular matrix, the reconstruction of the neo-tissue is successfully guided.